Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE takes another big step forward in early diagnosis of Alzheimer’s Disease: Aladdin gets extensive multimodal data from the largest Dementia platform in the UK
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Miscellaneous
Aladdin Healthcare Technologies SE takes another big step forward in early diagnosis of Alzheimer’s Disease: Aladdin gets extensive multimodal data from the largest Dementia platform in the UK – Aladdin gains access to 4 important data cohorts that include key genetic data for dementia research – DPUK has three million dementia patients’ data through multiple cohorts – This data sets the stage for significant potential breakthroughs for new biomarkers for a new affordable non-invasive global test BERLIN/LONDON, June 17, 2020 – Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, gained approval by the Dementias Platform UK (DPUK) for accessing important biobanks containing a huge amount of medical data for dementia research. This data sets the stage for significant potential breakthroughs for new biomarkers for a novel affordable non-invasive global test that would create a new gold standard for Alzheimer’s testing and place Aladdin at the forefront of new generation diagnostic leaders. Aladdin has recently gained approval for accessing the following cohort studies of DPUK, which are some of the richest data cohorts for dementia research: Whitehall II, BRACE, ELSA and Generation Scotland. This gives the Company the chance to improve its Artificial Intelligence (AI) assisted discovery process for early diagnosis of age-related neurodegenerative diseases. The new data can add significant new information to Aladdin’s proprietary Knowledge Graph and lead to more discoveries for new biomarkers. Gaining access to these valuable biobanks is a further evidence of Aladdin’s ability to work with renowned international research partners. This represents the first step towards a bigger project of closing an official partnership and becoming a consortium member of the DPUK. About Aladdin Healthcare Technologies SE Website Link: www.aladdinid.com For further information: Contact Press
17.06.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | info@aladdinid.com |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 1071751 |
End of News | DGAP News Service |